Dr. Reddy’s Laboratories (RDY) has announced a definitive agreement with Haleon plc (HLN) to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category, excluding the United States.The impending acquisition will add Nicotinell, Haleon’s leading NRT brand with a presence in more than 30 countries across the EU, Asia (including Japan) and Latin America, to RDY’s portfolio of global consumer healthcare over-the-counter (OTC) drugs. It also encompasses local ma ...